Swiss IVAL Pharma to invest $150 million in Uzbekistan plant to make insulin and other products

Switzerland-based IVAL Pharma AG is considering investing up to $150 million in the construction of a plant in the Tashkent region of Uzbekistan, sources in the Uzbek government have recently said.

The new plant will specialize in the production of insulin, antibiotics, vitamins and other drugs. It will be expected to be the sole producer of insulin in Uzbekistan and will fully cover the local needs for this drug. It will comprise several production sites and will have the total area of 20 hectares.

The capacity of the plant is expected to reach 500,000 tablets, 10 million doses of insulin and 100 million doses of infusion solutions a year. Most of the future production is expected to be supplied to the local market, however part of the products will be exported abroad.